공시 • Mar 30
Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026 Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 21, 2026. 공시 • Mar 17
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2025 Results on Mar 30, 2026 Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2025 results on Mar 30, 2026 공시 • Dec 10
Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million. Lee's Pharmaceutical Holdings Limited (SEHK:950) signed asset purchase agreement to acquire Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., for $15 million on December 8, 2025. A cash consideration of $10 million will be paid by Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited will pay an earnout/contingent payment of $5 million cash which will be paid on June 1, 2026.. As part of consideration, $15 million is paid towards assets of Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc.,.
Assets relating to Alexza Business of Alexza Pharmaceuticals, Inc., reported total common equity of $58.67 million as on December 31, 2024.
The expected completion of the transaction is December 8, 2025 to January 21, 2026. 공시 • Aug 15
Lee's Pharmaceutical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025 Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025 공시 • Mar 27
Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025 Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2025. 공시 • Mar 12
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2024 Results on Mar 27, 2025 Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2024 results on Mar 27, 2025 공시 • Aug 16
Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2024 results on Aug 28, 2024 공시 • Aug 02
Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong Lee's Pharmaceutical Holdings Limited announced that on 15 July 2024, the first patient has been enrolled in a Phase I clinical trial to receive AU409 at Queen Mary Hospital, Hong Kong. This trial focuses on patients with advanced hepatocellular carcinoma who have previously failed standard first-line treatment. AU409 is a novel drug discovered and owned by Auransa Inc. ("A Phase I, Single-arm, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients who failed Standard Treatment" is led by Principal Investigator Dr. Chi Leung Chiang, MD. The primary objectives are to determine the maximum tolerated dose and recommended Phase II dose, as well as to characterise the safety and tolerability of AU409. Secondary objectives include assessing the pharmacokinetics and preliminary anti-tumor activity of AU409. AU409 is a novel drug discovered and owned by Auransa Inc. ("Auransa"), and is manufactured by Zhaoke Pharmaceutical (Guangzhou) Limited, a wholly owned subsidiary of the Group, in compliance with the Good Manufacturing Practice regulations set by the U.S. Food and Drug Administration. This Phase I clinical trial marks the first-in-human study in Asia and is expected to conclude by the second quarter of 2025. The results of this study will be used for China's new drug registration purpose. 공시 • Jul 02
Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director The board of directors of Lee's Pharmaceutical Holdings Limited announced that after considering the recommendation of the nomination committee of the Company, the Board has appointed Mr. Huang Zuie Chin as a non-executive Director with effect from 2 July 2024. Mr. Huang, aged 59, has over 35 years' experience in the life science and investment industry together with 20 years' experience in the pharmaceutical and biotech industry holding senior roles in business development, sales, marketing and research and development. In 2011, he joined Kleiner Perkins Caufield & Byers China as a managing partner and focuses on the firm's life science practice. He is also the founding managing partner of Panacea Healthcare Venture Capital, including Panacea Venture Healthcare Fund I, L.P., Panacea Venture Healthcare Fund II, L.P. and Panacea Opportunity Fund I, L.P., which are venture capitals focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Mr. Huang received a Master of Business Administration (MBA) from the Stanford Graduate School of Business and a Bachelor of Science degree in chemical engineering from the University of California, Berkeley. He is a non-executive director of Kindstar Globalgene Technology Inc., whose shares are listed on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (Stock Code: 9960) since 2012, and a director of Connect Biopharma Holdings Limited, a company whose shares are listed on Nasdaq Global Market since 2024. Between 2020 and 2023, he was an executive director of Auto Italia Holdings Limited, whose shares are listed on the Stock Exchange (Stock Code: 720). Furthermore, Mr. Huang was the chairman of the board of directors of Alaunos Therapeutics Inc., whose shares are listed on NASDAQ Global Select Market, between 2021 and 2023. He was also a director of CASI PHARMACEUTICALS, INC., whose shares are listed on NASDAQ, between 2013 and 2023 and the chairman of the board of Windtree Therapeutics Inc., a company whose shares are listed on NASDAQ between 2019 and 2023. 공시 • Mar 27
Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024 Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024. Agenda: To consider and approve the final dividend in respect of the year ended 31 December 2023 of HK1.0 cent per share in an aggregate amount of HK$5,888,000; and to consider other matters. 공시 • Mar 26
Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 Lee's Pharmaceutical Holdings Limited proposed ordinary final dividend of HKD 0.01 per share for the year ended 31 December 2023. Date of shareholders' approval is 22 May 2024. Ex-dividend date is 28 May 2024. Record date is 31 May 2024. Payment date is 17 June 2024. 공시 • Mar 15
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Lee's Pharmaceutical Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 공시 • Aug 31
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023 Lee's Pharmaceutical Holdings Limited announced interim dividend of HKD 0.008 per share for the six months ended June 30, 2023. Ex-dividend date is 12 September 2023. Record date is 15 September 2023. Payment date is 04 October 2023. 공시 • Aug 19
Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023 Lee's Pharmaceutical Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023 공시 • May 18
Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director Lee's Pharmaceutical Holdings Limited approved to appoint Ms. Cheang Yee Wah, Eva as the independent non-executive director of the Company, at the AGM held on 17 May 2023. 공시 • Jan 20
Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List Lee's Pharmaceutical Holdings Limited announce that the Group's commercialised products, namely Treprostinil Injection, Teglutik® and Trittico® have been included for the first time into the updated National Reimbursement Drug List (the "NRDL") issued by the China National Healthcare Security Administration on 18 January 2023 and will be officially implemented from 1 March 2023. Together with the other 6 products in the list, a total of 9 products of the Group have been included in the updated NRDL. Among 111 products included for the first time in this updated NRDL, 7 of which are from rare disease area and the Group's Treprostinil Injecton and Teglutik® have taken up 2 places thereof. Together with Trittico®, the Group firmly believed that the newly inclusion of these specialty drugs into the updated NRDL will help the Group to further enhance the affordabilityand accessibility thereof among patients in rare disease and mental health areas. 
